SEC Form 4 · accession 0001209191-15-086152

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Dec 16, 2015

Accepted (ET)

Dec 18, 2015 · 5:22 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Dec 16, 2015	M	10,400	$35.64	A	275,684	D
Common Stock^F2,F3	Dec 16, 2015	S	2,000	$114.72	D	273,684	D
Common Stock^F2,F4	Dec 16, 2015	S	2,600	$115.72	D	271,084	D
Common Stock^F2,F5	Dec 16, 2015	S	4,400	$116.47	D	266,684	D
Common Stock^F2,F6	Dec 16, 2015	S	400	$117.73	D	266,284	D
Common Stock^F2,F7	Dec 16, 2015	S	1,000	$118.81	D	265,284	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock	holding	—	—		—	122,700	I	Common Stock held in trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F8	$35.64	Dec 16, 2015	M	10,400	D	—	Feb 1, 2016	Common Stock	10,400	63,200	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $114.72 (range $114.20 to $115.19).
F4Open market sales reported on this line occurred at a weighted average price of $115.72 (range $115.20 to $116.04).
F5Open market sales reported on this line occurred at a weighted average price of $116.47 (range $116.21 to $117.15).
F6Open market sales reported on this line occurred at a weighted average price of $117.73 (range $117.42 to $117.92).
F7Open market sales reported on this line occurred at a weighted average price of $118.81 (range $118.52 to $119.21).
F8Fully vested.